Published On: January 19th, 20210 Comments

Visit Canadian Psoriasis Biosimilar Position Statement to read their recommendations.

These recommendations include:

  1. If a drug plan is considering non-medical switching,
  2. If a drug plan is considering tiering
  3. All drug plans implementing biosimilar policies should conduct robust post-implementation surveillance.